Boston—Combination therapy with direct-acting antivirals (DAAs) and the cholesterol drug ezetimibe is effective at preventing or rapidly curing infection with hepatitis C virus in transplant recipients who have received organs from infected donors, a new study has concluded.
The short-course strategy employed by the investigators allowed patients to complete HCV therapy prior to discharge from the hospital after transplantation.
Jordan J. Feld, MD, MPH, the R. Phelan Chair in Liver Disease